Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Despite mounting evidence supporting the cardio-kidney benefits of sodium/glucose cotransporter 2 inhibitors (SGLT2i), significant disparities in their use exist among people with type 2 diabetes (T2D), cardiovascular, or kidney disease that reveals a significant disconnect between guidelines and practice. These discrepancies are particularly pronounced among women, minority races, and lower socioeconomic groups. These groups remain underrepresented in major cardiovascular trials, potentially leading to their exclusion from optimal therapies and increasing morbidity and mortality rates. This review aims to highlight disparities in the use of SGLT2i in populations with T2D, chronic kidney disease, heart failure, and atherosclerotic cardiovascular disease. It examines the factors that influence the prescription of SGLT2i within these populations and evaluates their downstream impact on clinical outcomes. Finally, the review summarizes recent clinical trial findings on strategies that enhance the adoption of SGLT2i and other cardioprotective agents through a multifaceted approach, aiming to improve real-world adoption for patients with T2D and/or cardiovascular and kidney diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Community health workers and patient navigators play a critical role in bridging healthcare systems with underserved communities by providing tailored education, assisting with appointment scheduling, and connecting patients to insurance and medication-assistance programs [27].”
From Unequal Access to Evidence-Based Cardiometabolic Therapies: Racial Disparities in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use Among Patients With Type 2 Diabetes and Cardiovascular Disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Notably, race and ethnicity explained about 26% of the variation, highlighting the ongoing impact of structural and financial inequities [27].”
The cited source says what the claim attributes to it.
In the citing paper
“However, financial barriers remain a major obstacle. Medication costs, out-of-pocket expenses, and insurance type continue to influence access to SGLT2 inhibitors and GLP-1 receptor agonists [27].”
The cited source says what the claim attributes to it.
In the citing paper
“In a study of over 3,000 adults with type 2 diabetes from the 2017-2018 Medical Expenditure Panel Survey, Medicare beneficiaries were less likely to receive these therapies compared with those with private insurance (OR 0.60; 95% CI, 0.36-0.99).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Structural racism and health inequities in the USA: evidence and interventions
Bailey, Z. D., Krieger, N., Agénor, M., Graves, J., Linos, N., & Bassett, M. T. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30569-x · Cited by 5,203
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Research works printed but not linked: 3
- National Institutes of Health, 2024, Minority Health and Health Disparities Strategic Plan 2021–2025
- Healthy People 2030, 2024, Priority Areas: Social Determinants of Health
- Healthy People 2030, 2024, Building a Healthier Future for All
Cited by
Vafeidou, K., Psoma, O., Apostolidis, E., Sarvani, A., Doumas, M. N., Kotsa, K., Tsimihodimos, V., & Koufakis, T. (2025) · Geriatrics · doi:10.3390/geriatrics10060144 · Cited by 8
“Reports often highlight higher uptake in academic or specialized centers compared to community practices [24].”
Obi, M. F., Ahmad, S., & Ezechukwu, K. (2026) · Cureus · doi:10.7759/cureus.106266 · Cited by 1
“Notably, race and ethnicity explained about 26% of the variation, highlighting the ongoing impact of structural and financial inequities [27].”
InfluentialYoung, C. F., O’Brien, K., Neumiller, J. J., Isaacs, D. M., Shubrook, J. H., & Clements, J. N. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0049
Avenatti, E., Sadhu, A., Gullapelli, R., Rao, A., Pavuluri, C., Nasir, K., & Kashyap, S. R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101733
“Policy reforms — such as price negotiations, generic options, and value-based formularies — are essential to promote equitable access [14].”
Self-citationTreleaven, L., Hong, A., Kiburg, K., Cording, A., O'Neal, D. N., & MacIsaac, R. J. (2026) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.70088
“20 This study has several limitations.”
Metadata
- Authors
- Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R.
- Affiliations
- Weill Cornell Medicine (US)
- Houston Methodist (US)
- Corresponding author
- Sadhu, Archana R
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2025-05-27
- Volume
- 110
- Issue
- 9
- Pages
- e2852-e2863
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC12342368
- OpenAlex
- W4410789150
- Cited by
- 9
- References
- 81
- Citations by year
- 2026: 8 · 2025: 1
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Weill Cornell Medicine
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 2 diabetes, health disparities, cardiorenal protection, chronic kidney disease, heart failure, atherosclerotic cardiovascular disease, underrepresentation in clinical trials, women, racial minorities, socioeconomic status, prescribing patterns, guideline adherence
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Healthcare Disparities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/clinem/dgaf301
- The paper
- Jack, G. A., Avenatti, E., Kashyap, S. R., & Sadhu, A. R. (2025). Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.